about
Melanoma Risk and Survival among Organ Transplant Recipients.Oncogene withdrawal engages the immune system to induce sustained cancer regression.Novel anti-melanoma treatment: focus on immunotherapy.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, MinnesotaSuccessful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.Biologically efficient solar radiation: Vitamin D production and induction of cutaneous malignant melanoma.Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.Skin cancer - an overview for dentists.Optimal management of skin cancer in immunosuppressed patients.Malignant melanoma in organ transplant recipients: incidence, outcomes, and management strategies: a review of literature.Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study.Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.Diagnosis and clinical management of melanoma patients at higher risk of a new primary melanoma: A population-based study in New South Wales, Australia.Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia.Ipilimumab in patients with melanoma and autoimmune diseaseLow intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma.UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer.Immune Checkpoint Inhibitors in Melanoma and HIV Infection.Melanoma in patients with GATA2 deficiency.Roles of UVA radiation and DNA damage responses in melanoma pathogenesis.Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.
P2860
Q27320787-827B6788-DED6-4F8A-82AF-CC77B002E8E3Q33987633-4AF58350-C6D3-4AF7-9890-BA1FA0FF7014Q34309404-9F2547C1-DAEA-4727-8C84-F7F492435614Q34361976-D94802D4-48AD-40BA-BDFB-B68D0ACD505FQ35690314-ECF85A69-B32F-43E9-AFCE-A6C9186A0C3FQ36910659-7AAF863E-D2CC-49C3-B530-C6930743AFC5Q37499923-EDB4F67E-2AB6-43FA-A32A-F312BE563723Q38185156-BA5C5C67-E66E-4943-BD9F-226847D75EFDQ38213896-85BF5704-3098-4033-8151-52A10476EBBFQ38228585-D99A25FE-892A-4D08-863C-647AA89D5170Q38605795-CA5D55EF-0D52-41FC-A2F0-8E44759CD272Q38682598-04EAF936-1C06-44AD-A7B6-FC02856493F2Q39312652-1C4BCF7E-C44F-4C00-A738-CCD248BABA65Q40394261-5216E85A-E1C9-48F2-9587-A2FE5506CA61Q41221077-CC9F206F-0CCA-4AD3-9153-4A79EE0F10A4Q41991133-3967D511-AB2C-4C84-A8F7-12341A1BAA5FQ42221103-196DA6A8-8083-4C9F-813A-D84BAD7EEE2FQ46721602-2DEF7CE3-5B77-4BAD-BE4C-486A83FE7242Q47138765-E3E902EA-C196-4806-8C83-D6962B875DABQ48270523-6186C9DB-EFA0-4B0E-844A-466F133F1927Q54983880-FA3BA395-C260-4954-A024-A07C6FB55167Q55352057-825E8A54-3038-442B-A4FD-924C4CB4FB98
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Melanoma in immunosuppressed patients
@ast
Melanoma in immunosuppressed patients
@en
type
label
Melanoma in immunosuppressed patients
@ast
Melanoma in immunosuppressed patients
@en
prefLabel
Melanoma in immunosuppressed patients
@ast
Melanoma in immunosuppressed patients
@en
P2860
P1476
Melanoma in immunosuppressed patients
@en
P2093
Agnieszka W Kubica
Jerry D Brewer
P2860
P304
P356
10.1016/J.MAYOCP.2012.04.018
P407
P577
2012-10-01T00:00:00Z